Drug Trial Radar · NCT00804115
The International Collaborative Exfoliation Syndrome Treatment Study
Last checked: Nov 19, 2026Latest source record: Dec 8, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
277
Actual
Start
Aug 2000
Primary completion
Sep 2007
Study completion Dec 2008
Sponsor
- Lead sponsor
- The New York Eye & Ear InfirmaryAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Pfizer
- First posted
- Dec 8, 2008
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years, up to 80 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Purpose: To determine the efficacy of treatment with latanoprost in combination with pilocarpine versus timolol or timolol/dorzolamide fixed combination (Timoptic or Cosopt) in eyes with XFS and elevated intraocular pressure (IOP). Methods: This is a randomized, open-label study to test the hypothesis that improving both pressure-dependent and pressure-independent aqueous outflow and minimizing iridolenticular friction will interfere with the progression of XFS, allow improvement in trabecular function, and be more effective over time than simply reducing aqueous formation. Randomization was performed across the centers, per patient rather than per eye to avoid any crossover effect caused by aqueous suppressants. Group I was treated with latanoprost and pilocarpine, both in the evening, and Group II with Timolol or Cosopt b.i.d. Only one eye per patient was randomized. Patients were followed for 2 years with assessment of IOP, visual field progression, tonographic outflow coefficient and trabecular pigmentation at the 6:00 and 12:00 position.
Conditions
- Exfoliation Syndrome
- Glaucoma
- Ocular Hypertension
Interventions
Latanoprost with Pilocarpine vs Timolol or CosoptDrug
Timolol 0.5% bid or Cosopt bid Latanoprost 0.005% qhs Pilocarpine 2%
Primary outcomes
What the sponsor says the trial is designed to measure.
- Latanoprost combined with pilocarpine (L-PILO) should be as effective as timolol or Cosopt in lowering IOPTime frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
New York Eye and Ear Infirmary
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.